Why the study?
Does alogliptin increase major adverse cardiovascular events in patients with type 2 diabetes who had had a recent acute coronary syndrome?
Does alogliptin increase major adverse cardiovascular events in patients with type 2 diabetes who had had a recent acute coronary syndrome?
Alogliptin does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome.
Supports alogliptin use post-ACS in type 2 diabetes; confirms cardiovascular safety in high-risk patients.
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
No takes yet. Share an insight, caveat, or question.
White et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: